Insider Buying: Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Acquires 80,000 Shares of Stock

Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) CEO Dirk Thye purchased 80,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was bought at an average cost of $1.24 per share, with a total value of $99,200.00. Following the completion of the purchase, the chief executive officer now owns 360,911 […]

Related Keywords

Wisconsin ,United States ,Dirk Thye ,Intellectus Partners ,Hennion Walsh Asset Management Inc ,Quince Therapeutics Inc ,Cortexyme Inc ,Nasdaq ,Renaissance Technologies ,Quince Therapeutics ,Get Free Report ,Therapeutics Trading Down ,Walsh Asset Management ,Wisconsin Investment Board ,Quince Therapeutics Daily ,Nasdaq Qncx ,Qncx ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,